[
    [
        {
            "time": "",
            "original_text": "北向资金交投意愿转淡连续3日净卖出，白酒、新能源均遭出货",
            "features": {
                "keywords": [
                    "北向资金",
                    "交投意愿",
                    "转淡",
                    "净卖出",
                    "白酒",
                    "新能源"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北向资金交投意愿转淡连续3日净卖出，白酒、新能源均遭出货",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "小摩增持泰格医药(03347)8.34万股，每股作价约120.60港元",
            "features": {
                "keywords": [
                    "小摩",
                    "增持",
                    "泰格医药",
                    "8.34万股",
                    "120.60港元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "小摩增持泰格医药(03347)8.34万股，每股作价约120.60港元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【首发】百因诺生物完成近2亿元A轮融资，加大CDMO和无血清细胞培养基的研发及生产平台建设投入",
            "features": {
                "keywords": [
                    "百因诺生物",
                    "A轮融资",
                    "2亿元",
                    "CDMO",
                    "无血清细胞培养基",
                    "研发",
                    "生产平台"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【首发】百因诺生物完成近2亿元A轮融资，加大CDMO和无血清细胞培养基的研发及生产平台建设投入",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]